# US 7,611,699 B2 · Methods of using cytokine zalpha11 ligand

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,699 B2
- Document ID: US7611699B2
- Status: Granted
- Kind: B2
- Application number: 11/551,349
- Filed: 2006-10-20
- Published: 2007-03-01
- Granted: 2009-11-03
- Earliest claimed: 1999-03-09
- Assignees: ZymoGenetics, Inc.
- Inventors: Julia E. Novak; Scott R. Presnell; Cindy A. Sprecher; Donald C. Foster; Richard D. Holly; Jane A. Gross; Janet V. Johnston; Andrew J. Nelson; Stacey R. Dillon; Angela K. Hammond
- Web page: https://patentgrep.com/patent/US7611699B2

## CPC

- C07K 14/001: {by chemical synthesis}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 38/18: Growth factors; Growth regulators
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/54: Interleukins [IL]
- C07K 14/5406: {IL-4}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2799/026: where the vector is derived from a baculovirus
- G01N 2333/52: Assays involving cytokines
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

## Claims

### Claim 1

A method of reducing the growth of cancer cells in a mammal comprising administering to a mammal in need thereof a therapeutically effective dose of a polypeptide as shown in SEQ ID NO:2 from amino acid residue 32 to residue 162, wherein reducing the growth of cancer cells results in a clinically significant improvement in the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the clinically significant improvement is reduction in time to progression.

### Claim 3 (depends on 1)

The method of claim 1, wherein the clinically significant improvement is reduction in the number of metastases.

### Claim 4 (depends on 1)

The method of claim 1, wherein the clinically significant improvement is tumor stasis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tumor is lymphoma.

### Claim 8

A method of stimulating an immune response in a mammal with melanoma comprising administering a therapeutically effective amount of a polypeptide comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid residue 32 to amino acid residue 162 to the mammal, wherein administration of the polypeptide to cells which comprise the melanoma reduces the growth of the cells and the stimulation of the immune response results in enhancement of an antitumor activity.

### Claim 9 (depends on 8)

The method of claim 8, wherein the anti-tumor activity results in a reduction in tumor progression.

### Claim 10 (depends on 8)

The method of claim 8, wherein the anti-tumor activity results in a decrease in metastasis.

### Claim 11 (depends on 8)

The method of claim 8, wherein the antitumor activity is tumor stasis.